FindTrial
Sign In

A New Conception About Individualized Treatment Allocation for HCC

A New Conception About Individualized Treatment Allocation for HCC-Using Machine Learning

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06008548
Acronym
PTA4HCC
Enrollment
4991
Registered
2023-08-23
Start date
2010-01-01
Completion date
2021-10-01
Last updated
2023-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCC, Resection, Transarterial Chemoembolization

Brief summary

The current guidelines on hepatocellular carcinoma (HCC) aimed to build effective prognostic stratification strategies to guide therapeutic allocation; however, the current guidelines did not consider the simultaneous comparison of distinct therapies in similar populations. Here, the investigators aimed to develop and validate a new, integrated prognostic scheme for HCC patients using artificial intelligence (AI) to simulate the survival outcomes of patients allocated to different treatments.

Detailed description

Given that liver resection (LR) and transarterial chemoembolization (TACE) are the mainstay curative and palliative therapies for HCC, respectively, patients who underwent LR or TACE were included in the study. Various prognostic AI algorithms were modeled using data from a large multi-institutional cohort, where LR and TACE were considered independent factors. The C-index, Brier score (BS), and area under the receiver operating characteristic curve (auROC) were calculated to estimate the AI models.

Interventions

PROCEDURETACE

Sponsors

Air Force Military Medical University, China
CollaboratorOTHER
Army Medical University, China
CollaboratorOTHER
The First Affiliated Hospital of Shanxi Medical University
CollaboratorOTHER
Sun Yat-sen University
CollaboratorOTHER
Shaanxi Provincial People's Hospital
CollaboratorOTHER
Xijing Hospital
CollaboratorOTHER
Xi'an Jiaotong University
CollaboratorOTHER
Tang-Du Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosed with HCC * Receiving LR or TACE therapy * Complete clinical information * Preserved liver function (Child-Pugh Score \[CPS\] ≤ 7) * PS 0-1

Exclusion criteria

* Vascular invasion or extrahepatic spread; * Ecompensated liver cirrhosis ; * Younger than 18 years; * Duration of follow-up of fewer than 30 days.

Design outcomes

Primary

MeasureTime frameDescription
overall survival5 yearsOverall survival (OS) was defined as the time interval between initial TACE or LR and all-cause death. Patients who survived up to the last follow-up date

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026